[1] Ferlay J,Soerjomataram I,Dikshit R,et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
[2] Torre LA, Bray F, Siegel RL,et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] Magne Nde CB,Zingue S,Winter E,et al. Flavonoids, breast cancer chemopreventive and/or chemotherapeutic agents[J]. Curr Med Chem, 2015, 22(30): 3434-3446.
[4] Maggioni D,Biffi L, Nicolini G,et al. Flavonoids in oral cancer prevention and therapy[J]. Eur J Cancer Prev, 2015, 24(6): 517-528.
[5] Novo Belchor M,Hessel Gaeta H,Fabri Bittencourt Rodrigues C,et al. Evaluation of rhamnetin as an inhibitor of the pharmacological effect of secretory phospholipase A2[J]. Molecules, 2017, 22(9). pii: E1441.
[6] Zhang W,Li B,Guo Y,et al. Rhamnetin attenuates cognitive deficit and inhibits hippocampal inflammatory response and oxidative stress in rats with traumatic brain injury[J]. Cent Eur J Immunol, 2015, 40(1): 35-41.
[7] Manu KA,Shanmugam MK,Ramachandran L,et al. Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-kappaB signaling cascade in gastric cancer[J]. Cancer Lett, 2015, 363(1): 28-36.
[8] Fan L,Strasser-Weippl K,Li JJ,et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-e289.
[9] 钮红岺, 黄晓萍, 刘晓珑, 等. 阿司匹林对血小板诱导的乳腺癌MCF-7细胞上皮间质转化和迁移侵袭能力的影响[J].中国临床解剖学杂志, 2017, 35(2): 183-187.
[10]Prasain JK,Rajbhandari R,Keeton AB,et al. Metabolism and growth inhibitory activity of cranberry derived flavonoids in bladder cancer cells[J]. Food Funct, 2016, 7(9): 4012-4019.
[11]Li Q,Ren FQ,Yang CL,et al. Anti-proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo[J]. Asian Pac J Cancer Prev, 2015, 16(7): 3035-3042.
[12]Hu S,Huang L,Meng L,et al. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogenactivated protein kinase kinase signaling pathways[J]. Mol Med Rep, 2015, 12(5): 6745-6751.
[13]Ramachandran L,Manu KA,Shanmugam MK,et al. Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor gamma activation pathway in gastric cancer[J]. J Biol Chem, 2012, 287(45): 38028-38040.
[14]Seo S,Seo K,Ki SH,et al. Isorhamnetin Inhibits Reactive Oxygen Species-Dependent Hypoxia Inducible Factor (HIF)-1alpha Accumulation[J]. Biol Pharm Bull, 2016, 39(11): 1830-1838.
[15]Li C,Yang D,Zhao Y,et al. Inhibitory effects of isorhamnetin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9[J]. Nutr Cancer, 2015, 67(7): 1191-1200.
[16]Gao XJ,Liu JW,Zhang QG,et al. Nobiletin inhibited hypoxia-induced epithelial-mesenchymal transition of lung cancer cells by inactivating of Notch-1 signaling and switching on miR-200b[J]. Pharmazie, 2015, 70(4): 256-262.
[17]Sun DW,Zhang HD,Mao L,et al. Luteolin inhibits breast cancer development and progression in vitro and in vivo by suppressing notch signaling and regulating miRNAs[J]. Cell Physiol Biochem, 2015, 37(5): 1693-1711.
[18]Kang J,Kim E,Kim W,et al. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines[J]. J Biol Chem, 2013, 288(38): 27343- 27357.
[19] El-Alfy TS, Ezzat SM, Hegazy AK, et al. Isolation of biologically active constituents from Moringa peregrina (Forssk.) Fiori. (family: Moringaceae) growing in Egypt[J]. Pharmacogn Mag, 2011, 7(26):109- 115. |